Pharmaceuticals, Biotechnology and Life Sciences
Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of…
MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused…
Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining…
– Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3…
Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical…
All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going…
– Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately…
Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan…
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma…
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) — DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming…